科兴生物制药股份有限公司自愿披露关于GB08注射液II期临床试验完成首例受试者入组的公告

Group 1 - The company announced the successful enrollment of the first subject in the Phase II clinical trial of GB08 injection, which is an innovative drug developed for children with growth hormone deficiency [1][2] - GB08 injection is the company's first self-developed Class I innovative drug, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of GB08 injection in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine [2] Group 2 - The successful enrollment of the first subject in the clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [3]